Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
about
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon betaBiomarkers of therapeutic response in multiple sclerosis: current statusBiomarkers of treatment response in multiple sclerosisDevelopment of oral immunomodulatory agents in the management of multiple sclerosisOccurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort AnalysisNeutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study.Interferon-beta1a: a once-weekly immunomodulatory treatment for patients with multiple sclerosis.The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis.The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levelsEarly detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.Neutralizing antibodies against interferon-BetaNeutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosisThe Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management.Neutralising antibodies to IFN-beta in patients with multiple sclerosis.Interferon-beta1b in multiple sclerosis.Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement.Treatment of multiple sclerosis: current concepts and future perspectives.Fabry disease, enzyme replacement therapy and the significance of antibody responses.Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosisGuidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.Evaluating response to disease-modifying therapy in relapsing multiple sclerosis.Registers of multiple sclerosis in Denmark.Development of interferon beta-neutralising antibodies in multiple sclerosis--a systematic review and meta-analysis.Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies.Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial.Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis.Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey.Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study.Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
P2860
Q26864418-7A5BB8B1-6397-4962-A87A-889DDF1B3543Q27012726-95AB0E6F-0867-41A3-907F-B94CF44E59EFQ28305094-971BA29B-A4D0-41F5-96C6-979DBD88C6CFQ28388704-54E844AA-90CC-4CD0-9048-FD4AF64EB916Q28553133-5B2D0156-23AC-486B-ACE9-ED646662EDC6Q33510256-EAA23BFD-F8C3-4196-972D-ED46381A898BQ33579409-FFD3F363-51E6-4070-A3DF-FB3F63364590Q33810082-CAFE6993-B775-4E46-9383-841EED03350AQ34207663-1CF7EB74-E49A-4274-9214-446306AC9EC3Q34368959-DB2BB683-AE3D-4A7E-8021-86679ABA2AF0Q34409082-944AB108-6E7D-4A17-9834-01F92EF9C40CQ34636829-710E2844-2656-4CFB-B38D-FEF5DC397296Q36070808-11280826-AC69-4096-9F2F-A33ECDFC2160Q36272813-0E7BD39D-DA29-4ADE-93CC-8B0814C210E0Q36419566-AA7DF76B-78DF-4FB1-8F41-7B27F169112EQ36541952-406FC0A5-C6B4-4E32-BA31-0D447F7D4765Q36752915-15291658-CCA6-4532-A21E-ACE29E7DD748Q36840374-FB01C59E-E7DB-4B70-AB75-1BA9D9F43A37Q37189729-3C8F1E83-C564-40D7-AEE9-A50D292E28E4Q37884434-980B7BC3-460E-4F01-8A7B-996BF9E5A4EFQ37950838-837D3C78-78C0-4793-BCDE-1B07C36AF416Q38070677-C9481A49-8F1A-45A4-BAF2-8569CA90585EQ38174450-097FFA29-F5AA-4109-8462-BEFF16E2372FQ38375605-95585D1E-3F66-4470-9AD9-622C23825D95Q38517156-A1367424-BF37-42DC-8220-99E16EDCDDBBQ38565662-55D482F6-DA88-41AD-A401-45553B409453Q38960854-994AF444-6B08-4A9A-8E8F-C5806ADB866CQ40144737-6481FC19-289E-423B-8714-9F56CD4FF9A8Q40177428-40CAD350-EA21-4D67-80AC-FE9DD4F07D5FQ41845400-BE0F1FB0-D29B-4B04-9B4F-094DB8AD532BQ42160940-56FD510C-8218-4822-AF74-0B1A11B93573Q42375591-90B40355-1A77-4F66-8370-38E8694C6978Q42578789-18D9F6D7-434D-4EF3-A9D4-05EC94E8FC31Q42687809-AE78EB07-D490-4589-A8A9-0C268FFFBDC2Q43228872-39023AB5-36BE-4E24-8BD1-A30AF4744389Q43520925-08111006-8A3E-400D-94A5-13DA85A9C127Q43997002-B5BED9C2-28FE-4A0E-A260-45D71B8EEF96Q44258171-AADC73EA-BE0A-4108-A72F-188F5A63AA99Q45807781-916FE012-CDAA-43C4-A36D-E257CA63FBA1Q45998750-FFF7BDF0-6917-47AD-92B4-8908FE2BA2A7
P2860
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
@en
type
label
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
@en
prefLabel
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
@en
P2093
P1433
P1476
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
@en
P2093
Danish Multiple Sclerosis Study Group
K Bendtzen
K M Clemmesen
N Koch-Henriksen
P356
10.1212/01.WNL.0000166049.51502.6A
P407
P577
2005-05-11T00:00:00Z